Parkinson’s and diabetes
Cure Parkinson’s Fundraising Heroes: January 2025
The funds and awareness raised by our Fundraising Heroes helps support our vital research seeking to slow, stop or reverse Parkinson’s – we couldn’t do it without you! Fundraising…
Spring Research Update Meeting 2025
Our 2025 Spring Research Update Meeting will take place at BMA House, home of the British Medical Association, in Tavistock Square, London on 24 March where we invite guests…
Webinar: Addressing the sex and gender gaps in Parkinson’s research
To mark International Women’s Day, Cure Parkinson’s and Parkinson’s UK are hosting a free webinar on March 6, 2025 at 5:00 pm GMT. Women are drastically underrepresented in Parkinson’s…
Win a framed silkscreen print by acclaimed Cure³ artist Bruce McLean!
Our latest exciting raffle for aa framed silkscreen print by acclaimed Cure³ artist Bruce McLean raised over £1600 for our research. Thank you! Read on to find out more about…
Ozzy Osbourne and Black Sabbath announce farewell concert supporting three charities… including Cure Parkinson’s!
We are delighted to be a beneficiary of Black Sabbath’s Back to the Beginning show, held on 5 July at Villa Park. The farewell gig will see the original…
Exenatide-PD3 results published
The full results of the Exenatide-PD3 study, a phase 3 clinical trial of Type 2 diabetes drug exenatide (Bydureon), have now been published. They report that the study unfortunately…
Remembering a loved one with in memory giving
Honouring a loved one’s memory through charitable giving is a deeply meaningful way to celebrate their life and make a lasting difference. In memory donations not only pay tribute…
Prioritising the most promising drugs for Parkinson’s: our new drug screening project
Cure Parkinson’s is excited to announce funding for a pre-clinical project that aims to test, evaluate and compare drugs that have the potential to slow Parkinson’s progression. Established by…
Limited edition album ‘Think Loud’ to support Cure Parkinson’s
Music legends from the worlds of rock and folk have come together to create an exclusive double album to help raise funds and awareness for Cure Parkinson’s. Kindred Spirit…
Cure Parkinson’s Fundraising Heroes: December 2024
2024 was a phenomenal year of fundraising for Cure Parkinson’s, and we’d like to say a huge thank you to everyone who helped raise vital funds and awareness for…
2025: Cure Parkinson’s research highlights from the last year and insights for the year ahead
2024 was another busy year for the research team at Cure Parkinson’s; from the results publication of the phase 2 clinical trial of lixisenatide to the funding of new…
The road ahead: 2025 (part 1)
The first post at the start of each year on the SoPD website has traditionally tried to provide an overview or some context on where things are in…
Webinar: Advancing Parkinson’s trial designs
Held in partnership with the University of Edinburgh and the Journal of Parkinson’s Disease, with Edinburgh University’s Professor Tilo Kunath as chair. Robust, high-quality clinical trials can take years…
Cure Parkinson’s Fundraising Heroes: November 2024
In November, three fundraising heroes embarked on a 300km cycling challenge, plus one supporter appeared on a popular ITV gameshow! From Brussels to Luxembourg by bike Supporter Nick, who…
Get your paws on a #SophieFromRomania calendar in time for Christmas
We’ve worked with our patron Rory Cellan-Jones to create a gorgeous 2025 calendar, featuring his beautiful rescue dog turned social media sensation, Sophie! Following the success of our recent…
Cure³ announced for 2025
Featuring works by artists Frank Bowling, Bouke de Vries and Rana Begum, acclaimed selling exhibition Cure³ will be returning for a fifth edition in 2025 to raise funds and…
Cure Parkinson’s fundraiser beats the Banker on Deal or No Deal
Supporter Craig appeared on the latest series of the iconic TV game show and raised valuable awareness for Cure Parkinson’s during his episode. Craig (who featured on episode 12…
Cure InSight: Cure Parkinson’s Autumn 2024 Newsletter
Download the latest edition of our biannual newsletter, Cure InSight, and find out more about the newest developments in research, fundraising and advocacy for Cure Parkinson’s. Our latest update…
The Big Give Christmas Challenge 2024
The Big Give Christmas Challenge is the UK’s biggest match-funded campaign and Cure Parkinson’s is delighted to have been chosen as one of its beneficiaries again in 2024. If…
How testing the gut could help in the early detection of Parkinson’s
Recent results from a Cure Parkinson’s funded study have provided more evidence for a possible role of the gut in Parkinson’s, as well as identifying new markers to aid…
Insights on grant applications and research funding from our latest Research Committee interns
At the end of 2023, Cure Parkinson’s set up an internship scheme for PhD students or early post-doctoral researchers to join our Research Committee for a one-year period. This…
October Walking Challenge raises over £63k for Cure Parkinson’s
Our amazing supporters challenged themselves to walk 100km throughout the month of October to raise vital funds for Parkinson’s research. Over the past couple of years we’ve organised virtual…
Cure Parkinson’s Fundraising Heroes: October 2024
In October, many of Cure Parkinson’s fundraising heroes laced up their trainers to run in support of our research. But running wasn’t the only challenge our fundraisers got up…
Our latest pre-clinical research project: evaluating the neuroprotective properties of ‘CP-6’
Cure Parkinson’s is excited to announce funding for a new pre-clinical study of ‘CP-6’ for Parkinson’s led by Dr Marco Fazzari and his team at the University of Pittsburgh….
Autumn Research Update Meeting 2024: watch again
Our 2024 Autumn Research Update Meeting once again took place at the renowned Royal Society of Medicine (RSM), Wimpole Street, London on 27 November, where we invited guests to…
Emeli Sandé and Peter Andre headline Cure Parkinson’s Gala at the Roundhouse
On Monday 7 October, a star-studded line up led by pop music icons Emeli Sandé and Peter Andre, gathered at the Roundhouse in Camden to support a fundraiser for…
Cure Parkinson’s Fundraising Heroes: September 2024
Our fundraising heroes headed to France for some unique (and adrenaline filled) challenges in September. A Mont Blanc mission Father and son duo Hugh and Eddie embarked on a…
Press Release: 2024 Tom Isaacs Award honours Parkinson’s expert Professor Oliver Bandmann
26 September 2024 Cure Parkinson’s and Van Andel Institute (VAI) are delighted to announce Professor Oliver Bandmann as the winner of the 2024 Tom Isaacs Award, which honours researchers…
2024 Tom Isaacs Award honours Parkinson’s expert Professor Oliver Bandmann
Cure Parkinson’s and Van Andel Institute (VAI) are delighted to announce Professor Oliver Bandmann as the winner of the 2024 Tom Isaacs Award, which honours researchers who closely collaborate…
Win a unique portrait of #SophieFromRomania!
Our raffle offering you the chance to win a unique portrait of #SophieFromRomania is now closed. Thank you to everyone who participated – together we raised over £2,500 for…
Cure Parkinson’s supporters raise over £21k with the Celtic Challenge
A group of Cure Parkinson’s fundraisers set out on a 200 mile cycling challenge across Scotland. On 4 September, 15 Cure Parkinson’s supporters (including three living with Parkinson’s) set…
Cure Parkinson’s Fundraising Heroes: August 2024
Cure Parkinson’s Fundraising Heroes walked, cycled, danced and sang to raise funds and awareness for us in August. Walking the Pembrokeshire Coast Path for Parkinson’s Rebecca and Lily dedicated…
Rallying to the Challenge 2024: recorded to watch again
Rallying to the Challenge is a meeting designed for and by people with Parkinson’s, advocates and care partners to explore how the Parkinson’s community can impact and accelerate research.
Share your thoughts on lumbar punctures in Parkinson’s research
Cure Parkinson’s is conducting a new online survey to explore patient perspectives on the use of lumbar punctures in Parkinson’s research and clinical trials. Developed in collaboration with the…
Webinar: Innovations in gene therapies for Parkinson’s
Held in partnership with the University of Edinburgh and the Journal of Parkinson’s Disease, with Edinburgh University’s Professor Tilo Kunath as chair. The next in our one hour quarterly…
Win 2 tickets to see Taylor Swift at Wembley Stadium!
Thank you to everyone who took part in our raffle for Taylor Swift tickets! Together you helped raise over £3200 for our vital work. Congratulations to supporter Paul from…
Cure Parkinson’s Fundraising Heroes: July 2024
July’s Fundraising Heroes laced up their walking boots or donned their lycra to support Cure Parkinson’s. A Blencathra Bat Mitzva challenge For Maya’s Bat Mitzvah challenge, she decided to…
Cycling into the Arctic Circle for Parkinson’s
A team of 22 cyclists, including Cure Parkinson’s trustee Alison Anderson, take on a 600km cycle through Norway to the capital of the Arctic. Setting off on 3 August…
Parkinson’s drug therapies in the clinical trial pipeline: 2024 update
Each year, members of the Cure Parkinson’s research team collaborate with Parkinson’s research advocates and The Michael J. Fox Foundation to present an overview on the current clinical trials…
Parkinson’s and dementia: improving cognitive measures to enable better treatments
Recently, several international Parkinson’s and Dementia with Lewy Bodies (DLB) advocacy organizations, including Cure Parkinson’s, held a roundtable to discuss the development of better tools for measuring cognitive changes…
Pedaling from Peckham to Penzance, for Parkinson’s
Cure Parkinson’s supporters take on 500km charity bike ride to raise funds and awareness for our research, with the team raising more than £31k for us! Brothers Max and…
Our two newest pre-clinical research projects
Cure Parkinson’s is pleased to announce the funding for two new projects as part of our annual iLCT Pipeline Research Acceleration Grant Programme.
Cure Parkinson’s Fundraising Heroes: June 2024
Find out what some of Cure Parkinson’s supporters have been up to recently. The London to Brighton bike ride 15 Cure Parkinson’s fundraisers took part in the 2024 London…
Press Release: Cure Parkinson’s welcomes Mike Ashton as new chair of trustees
18 June 2024 Mike Ashton joined the board towards the end of 2023, bringing with him extensive experience in business growth strategy, brand and marketing management and governance in…
Cure Parkinson’s BBC Radio 4 Appeal with Paul Mayhew-Archer
TV writer, comedian, and Movers & Shakers podcaster Paul Mayhew-Archer presents a BBC Radio 4 Appeal on behalf of Cure Parkinson’s. This three minute, weekly programme highlights the work…
Cure Parkinson’s welcomes new chair of trustees
We are pleased to announce that Mike Ashton will step into the role of chair of our board of trustees. Mike joined the board towards the end of 2023,…
STEM-PD, a cell-replacement trial for Parkinson’s, releases latest update
The STEM-PD trial has recently released an update, which indicates the team is proceeding to the next trial stage based on early positive safety data.
Cure InSight: Cure Parkinson’s Spring 2024 Newsletter
Download the latest edition of our biannual newsletter, Cure InSight, and find out more about the newest developments in research, fundraising and advocacy for Cure Parkinson’s. Read about the…
Cure Parkinson’s Fundraising Heroes: May 2024
Our amazing fundraisers went the extra mile in May to raise vital funds in support of our research. Andy and the Glen Shiel Warriors Andy had planned to follow…
Clinical trial of lithium in Parkinson’s set to begin
We are delighted to announce funding for an upcoming phase1b clinical trial to investigate whether lithium, a drug currently used to treat mood disorders, could be repurposed to slow…
Cure Parkinson’s Fundraising Heroes: March and April 2024
Take a look at what our incredible fundraisers got up to in March and April. Putting in the steps to raise funds for our research Friends Tim (who lives…
Webinar: Inflammation and Parkinson’s
Held in partnership with the University of Edinburgh and the Journal of Parkinson’s Disease, with Edinburgh University’s Professor Tilo Kunath as chair. This hour-long webinar is for the Parkinson’s…
Over £140k raised for Cure Parkinson’s at the 2024 TCS London Marathon
Team Cure hit the streets of London to take part in the gruelling 26.2 mile race. On Sunday 21 April, 44 Cure Parkinson’s supporters ran the iconic TCS London…
Accelerating Parkinson’s drug development: The International Linked Clinical Trials initiative
In 2012, Cure Parkinson’s joined forces with Van Andel Institute (VAI) to hold the first international Linked Clinical Trials (iLCT) meeting in Grand Rapids, Michigan. The Committee has since…
Press Release: Fundraiser of the Year 2023
11 April 2024 We are thrilled to announce that we have two winners of our 2023 Fundraiser of the Year Award: Antony Rose and Michelle Gillies! These two incredible…
Fundraiser of the Year Award 2023
We are thrilled to announce that we have two winners of our 2023 Fundraiser of the Year Award: Antony Rose and Michelle Gillies! These two incredible supporters went ‘above…
2024 Planning for Prevention of Parkinson’s Conference
The 2024 Planning for Prevention of Parkinson’s: A Trial Design Forum conference will be held from May 5-7 in Boston, Massachusetts, US, this conference is intended to bring together…
Phase 2 trial results of lixisenatide published
The full results of the one-year, phase 2 clinical trial of Type 2 diabetes drug lixisenatide have now been published. This Cure Parkinson’s co-funded trial has reported positive results,…
Press Release: Phase 2 clinical trial of Type 2 diabetes drug for treatment of Parkinson’s shows positive and promising results
3 April 2024 Results from a one-year, phase 2 clinical trial of the Type 2 diabetes drug lixisenatide suggest that the treatment may slow the progression of motor symptoms…
Upcoming GBA1 conference in Montreal
Cure Parkinson’s is co-sponsoring a large three-day international conference on June 27th – 29th that will be focused on all aspects of GBA1 research, from basic science to clinical…
Time to ROCK-PD
Researchers in Germany are conducting a new phase 2 clinical trial to determine if an existing cardiovascular drug called fasudil, could help people with Parkinson’s.
INSIGHT Conference with PD Warriors 2024
Join global Parkinson’s leaders during World Parkinson’s Awareness Month at INSIGHT to PD, brought to you by PD Warrior, the pioneer behind the world’s most comprehensive Parkinson’s rehabilitation program….
The Movers & Shakers ‘Parky Charter’ petition
We are supporting the Movers & Shakers, along with Parkinson’s UK and Spotlight YOPD, to call on the government to take action to improve the lives of people with…
International Women’s Day and Parkinson’s
On 8 March, we celebrate International Women’s Day by shining a light on the work of female researchers and scientists who have made significant contributions to the Parkinson’s community,…
Cure Parkinson’s Fundraising Heroes: February 2024
February’s fundraising heroes have all taken on long term fundraising events to support our research. An untraditional triathlon Fundraising heroes Phil and Sue created their own triathlon-inspired challenge to…
The Power of HIIT for Parkinson’s
A small pilot study has found that high-intensity interval training – or HIIT – can have positive effects for people with Parkinson’s, both on overall well-being and potentially on…
Latest updates in the field of neurotrophic factors in Parkinson’s
Neurotrophic factors such as GDNF are still being actively investigated as a potential treatment for Parkinson’s, and alternative methods of delivery are currently being explored.
Press Release: Phase 2 clinical trial of dapansutrile for Parkinson’s confirmed
23 February 2024 Cure Parkinson’s, in partnership with Van Andel Institute, is delighted to announce funding for a Phase 2 clinical of dapansutrile, an anti-inflammatory drug, to determine whether…
Phase 2 clinical trial of dapansutrile for Parkinson’s confirmed
Cure Parkinson’s, in partnership with Van Andel Institute, is delighted to announce funding for a Phase 2 clinical of dapansutrile, an anti-inflammatory drug, to determine whether it can slow…
Webinar: Women with Parkinson’s – addressing sex and gender gaps in research
To mark International Women’s Day, Cure Parkinson’s is hosting a webinar on 5 March at 8:00 pm – do join us for what promises to be a lively and…
Spring Research Update meeting 2024: watch again
Our Spring Research Update Meeting once again took place at the renowned Royal Society of Medicine, Wimpole Street, London where we invited guests to an inspiring agenda of some…
Cure Parkinson’s Fundraising Heroes: January 2024
It’s a great time of year to start thinking about trying something new, so get inspired by some of our 2023 fundraising heroes who came up with some brilliant…
Press Release: Cure Parkinson’s welcomes Rory Cellan-Jones as new patron
7 February 2024 Cure Parkinson’s is delighted to announce that Rory Cellan-Jones, former technology correspondent for the BBC, writer, ‘Movers & Shakers’ podcaster, technology advisor and owner of one…
Cure Parkinson’s welcomes Rory Cellan-Jones as new patron
Cure Parkinson’s is delighted to announce that Rory Cellan-Jones, former technology correspondent for the BBC, writer, ‘Movers & Shakers’ podcaster, technology advisor and owner of one the UK’s most…
Moving towards a new staging system for Parkinson’s
Cure Parkinson’s has been a part of a group of Parkinson’s scientists, charity organizations, and patient advocates from around the world to help develop a new biological staging framework…
Webinar: Diet and the gut vs the brain
Held in partnership with the University of Edinburgh and the Journal of Parkinson’s Disease, this webinar focuses on the relationship between the gut and nutrition and Parkinson’s, and the…
Cure Parkinson’s welcomes five new trustees
Cure Parkinson’s has grown rapidly in recent years, influencing and funding increasingly larger projects with the goal of moving the research forward faster than ever. As part of our…
2024: research highlights of last year and the year ahead
With the announcement of some very encouraging results from completed clinical trials last year, and a number of promising new projects focused on disease modification – the outlook for…
Webinar: Parkinson’s research highlights from 2023 and what to look out for in 2024
No Silver Bullet 4 Parkinson’s and Cure Parkinson’s are delighted to invite you to join their webinar with Dr Simon Stott.
Cure Parkinson’s Fundraising Heroes: December 2023
To mark the start of a new year, we’re looking back at some fundraising heroes who completed long-term fundraising challenges in support of our research. From bake sales to…
Cure Parkinson’s Director of Clinical Development, Dr Richard Wyse, named onHis Majesty The King’s New Year’s Honours List
2 January 2024 Cure Parkinson’s Director of Clinical Development, Dr Richard Wyse, has been selected for His Majesty The King’s New Year’s Honours List, for services to medicine in…
Dr Richard Wyse named in His Majesty The King’s New Year’s Honours List
Dr. Richard Wyse, Cure Parkinson’s Director of Clinical Development, has been recognised with a prestigious inclusion in His Majesty The King’s New Year’s Honours List, for services to medicine…
Alpha-synuclein or Tau in Parkinson’s?
The build-up of a protein called alpha-synuclein has been considered one of the hallmarks of Parkinson’s. Recently, however, a group of scientists have called into question the ‘bad guy’…
Exploring Perspectives on Trial Design for Parkinson’s: An Update on the Delphi Study
Recently, Cure Parkinson’s was pleased to see the results of one of our funded studies published in the Journal of Parkinson’s Disease.
A Review of Our 2023 Preclinical Projects
In 2023, Cure Parkinson’s has funded five new preclinical projects. These preclinical projects address a wide range of ‘targets’ to understand which drugs and which targets should be further…
Cure Parkinson’s Research Committee Internship
Cure Parkinson’s is opening a new internship opportunity for young-career researchers to participate in our grant application process by joining our Research Committee.
Webinar: Stem cell research for Parkinson’s – the latest updates
The next instalment of this quarterly webinar series will discuss the latest news in cell replacement therapies for Parkinson’s with Edinburgh University’s Professor Tilo Kunath as chair.
The Big Give Christmas Challenge 2023
The Big Give Christmas Challenge is the UK’s biggest match-funded campaign and Cure Parkinson’s is delighted to have been chosen as one of the beneficiaries of this year’s campaign….
Autumn Research Update Meeting 2023: recorded to watch again
Our Research Update Meeting took place at the Royal Society of Medicine where we welcomed our many supporters to presentations of some of our funded research. The Cure Parkinson’s…
Facebook challenge raises £43k in support of Cure Parkinson’s research
170 Cure Parkinson’s supporters wrapped up warm to walk 100km this October. The challenge was to walk 100km over the month of October, encouraging people to get outside come…
Cure Parkinson’s Autumn Research Update meeting – 2023
Cure Parkinson’s is a medical research charity that is focused on disease modification for Parkinson’s. Our only goal is to slow, stop or reverse the condition. To achieve…
A new potential biomarker for Parkinson’s
Researchers at Duke University have recently presented data on a new potential biomarker for Parkinson’s.
Our first pipeline project of research
Our first project from our Research Pipeline Acceleration Programme is now underway. Professor Michael Schwarzchild is investigating evidence needed to determine if three iLCT-evaluated compounds are ready to progress…
2023 Tom Isaacs Award honours Dr Natasha Fothergill-Misbah
29 September 2023 Cure Parkinson’s and Van Andel Institute (VAI) are delighted to announce Dr Natasha Fothergill-Misbah, Research Associate at Newcastle University, as the winner of the 2023 Tom…
2023 Tom Isaacs Award honours Dr Natasha Fothergill-Misbah
Cure Parkinson’s and Van Andel Institute (VAI) are delighted to announce Dr Natasha Fothergill-Misbah, Research Associate at Newcastle University, as the winner of the 2023 Tom Isaacs Award. The…
NoSilverBullet4PD Webinar: How Parkinson’s impacts a woman’s life
In this upcoming webinar on Monday 9 October, the No Silver Bullet 4 Parkinson’s team will be joined by Parkinson’s advocates Richelle Flanagan and Annelien Oosterbaan to discuss the…
New research exploring ethnic diversity in Parkinson’s
A recent study from the Global Parkinson’s Genetic Program found a novel genetic risk factor for Parkinson’s in people of African ancestry. This finding once again brings to light…
UK joins Horizon Europe giving access to new research grants
On 7 September, the UK rejoined Horizon Europe, the world’s largest research collaboration programme, with exciting opportunities for research funding and collaboration.
‘Seeing’ the early signs of Parkinson’s
Researchers from University College London and Moorfields Eye Hospital investigated retinal imaging as a potential diagnostic tool for Parkinson’s. The group found changes in the retinas in people with…
The new Multi-arm Multi-stage MAMS trial model for Parkinson’s
One of the most frustrating aspects of the way we currently conduct clinical trials is the long delays between studies. Multi-Arm, Multi-Stage (or MAMS) clinical trials may represent a…
Drug repurposing for Parkinson’s – No Silver Bullet 4 Parkinson’s webinar
Cure Parkinson’s funded researcher Dr Lorraine Kalia will be presenting the NoSilverBullet4PD webinar this September discussing ‘Drug repurposing for PD therapies’.
Preliminary phase 2 trial results of lixisenatide presented
A one-year, phase 2 clinical trial of Type 2 diabetes drug lixisenatide has reported positive early results, which indicate that the treatment may slow the progression of motor (or…
Aspen starts phase 1 stem cell transplant clinical trial
An experimental treatment for Parkinson’s involves the replacement of the lost dopamine neurons by transplanting new cells into the brain. Biotech company Aspen Neuroscience will soon be starting a…
Helen Matthews takes the helm as new CEO of Cure Parkinson’s
10 August 2023 We are delighted to announce that Helen Matthews will be taking over as CEO of Cure Parkinson’s later this summer. As our current Deputy CEO and…
Rallying to the Challenge 2023: recorded to watch again
Rallying to the Challenge is a meeting designed for and by people with Parkinson’s, advocates and care partners to explore how the Parkinson’s community can impact and accelerate research.
UK sleepwalking into Parkinson’s pandemic
Cure Parkinson’s has today published the results from our recent survey revealing an alarming lack of knowledge about the world’s fastest growing neurological condition. We are dedicated to finding…
Webinar: World Parkinson Congress insights
During this webinar, chaired by Edinburgh University’s Professor Tilo Kunath, we hear from our panelists about which WPC sessions they found most useful and why they found them so…
NEXT create bouquet in support of Cure Parkinson’s
Cure Parkinson’s has teamed up with NEXT to bring you a special fundraising floral display this summer!
Upcoming webinar: The quest to cure Parkinson’s
Hosted online by the Royal Society of Edinburgh, top researchers from Dundee University will discuss the latest Parkinson’s research taking place in Dundee and the real-world impacts it will…
New data supporting neurotrophic factor as a potential treatment for Parkinson’s
An article in the Journal of the International Movement Disorders Society reports on some pre-clinical (laboratory) data supporting the development of ‘Glial cell line-Derived Neurotrophic Factor’ (GDNF) as a…
Jon Goodwin is an astronaut, and has Parkinson’s
In the first private astronaut mission of its kind, Jon Goodwin was a member of the passenger crew on board Virgin Galactic’s VSS Unity. Jon was diagnosed with Parkinson’s…
The 2023 International Linked Clinical Trials meeting
In June, Cure Parkinson’s gathered 23 of the world’s leading Parkinson’s experts together for the annual International Linked Clinical Trials (iLCT) meeting. The iLCT committee was created in 2012…
Positive phase 1 results for BlueRock
BlueRock Therapeutics has reported positive results from the phase 1 trial of its cell-replacement therapy for Parkinson’s
World Parkinson’s Congress 2023
There is no other meeting in the Parkinson’s space that is quite like the World Parkinson Congress! Hosted for the first time in 2004, the World Parkinson Congress (WPC)…
Cure Parkinson’s Raid Ventoux (Club des Cinglés Challenge) 2023
The fabulous Cure Parkinson’s Raid Series returned in June with the much anticipated Raid Ventoux (Club des Cinglés Challenge). Ascending Mont Ventoux is a feat loved by over 100,000 cyclists…
Helen Matthews to be new CEO of Cure Parkinson’s
We are delighted to announce that Helen Matthews will be taking over as CEO of Cure Parkinson’s later this summer. As our current Deputy CEO and former COO, Helen…
The UP Study results
Preclinical data have suggested that the bile acid Ursodeoxycholic acid (or UDCA) has neuroprotective properties in models of Parkinson’s. Researchers in Sheffield have led much of this research…
Bonhams sale of Romanée-Conti 2002 in support of Cure Parkinson’s
Cure Parkinson’s is delighted that Bonhams will be auctioning a six-bottle case of Romanee-Conti 2002, Domaine de la Romanée-Conti at its Fine Wines & Spirits Sale in London on…
Positively Parkinson’s return with the Big Tri 2023
The Big Tri will see the Positively Parkinson’s team take on an epic swim, cycle and hike to raise vital funds for Cure Parkinson’s. Back in 2021, 12 members…
Parkinson’s drug therapies in the clinical trial pipeline: 2023 update
Cure Parkinson’s has collaborated annually with Parkinson’s advocates and the Michael J Fox Foundation to present an update on the clinical trials landscape for Parkinson’s. The 2023 report is…
Phase 2 UDCA in Parkinson’s trial results published
Cure Parkinson’s is excited to announce that the results from the ‘UP Study’ – a phase 2 study of the liver drug UDCA in Parkinson’s – will be published…
Cure Parkinson’s CEO discusses hope for a cure with the Movers & Shakers
The latest episode of the hugely popular Movers & Shakers podcast features our very own Will Cook, CEO of Cure Parkinson’s. This episode, which also features University College London’s…
Our 2023 research impact report
Our recent research impact report determines and highlights the impact our research funding has had on the Parkinson’s research field.
65-year-old with Parkinson’s to run 970 miles in support of our research
Neil Russell will be running from London to Barcelona to raise money for Cure Parkinson’s and Parkinson’s UK. Neil, from Bourton-on-the-Water, is aiming to run over 970 miles in…
Inspirational Cure Parkinson’s supporter cycling to Barcelona in time for WPC
Keen cyclist and longtime Cure Parkinson’s supporter Alison Anderson will be cycling from Brighton to Barcelona to raise funds and awareness for us. Alison, who was diagnosed with Parkinson’s…
Four-legged fundraisers generate over £29k for Cure Parkinson’s
Over 170 incredible supporters and their dogs got out and about for our first ever Dog Walking Challenge! For our first ever Facebook fundraising challenge we asked people to…
Over £124k raised for Cure Parkinson’s at 2023 TCS London Marathon
On Sunday 23 April, 44 Cure Parkinson’s supporters laced up their trainers for the 2023 TCS London Marathon, raising an incredible amount for our research. Despite the rain #TeamCure…
A biomarker for Parkinson’s?
New research from an international consortium led by the Michael J Fox Foundation has highlighted a potential biological biomarker for Parkinson’s.
A new case for GCase
Low levels of a protein called GCase is associated with an increased risk of developing Parkinson’s. New understandings of the role of GCase could help to further explain other…
New clinical trials targeting the LRRK2 gene
LRRK2 is a protein that becomes hyperactive in some people with Parkinson’s, and this is believed to be involved in the progression of their Parkinson’s.
Just a lysosomal enzyme…
About 5% of individuals affected by Parkinson’s carry a genetic variation in a region of their DNA called the GBA1 gene. This area of DNA provides the instructions…
Fundraiser of the Year 2022
11 April 2023 We were delighted to announce the winner of our 2022 Fundraiser of the Year award as the remarkable Simon Cooper. Simon was instrumental in nominating Lloyd’s…
Think Loud: Leo Sayer joins industry legends to release charity single for Parkinson’s
Strictly theme co-composer and Procol Harum organist Josh Philips has joined forces with producer Paul Mitchell and legendary music manager Ian Grant to create a new, original track to…
Marking World Parkinson’s Day – tell us your story
Cure Parkinson’s has always had the unwavering belief that people living with Parkinson’s are key to finding the cure – and on World Parkinson’s Day we want to hear…
Simon Cooper – Fundraiser of the Year 2022
We were delighted to announce the winner of our 2022 Fundraiser of the Year award as the remarkable Simon Cooper! Simon was instrumental in nominating Lloyd’s syndicate AEGIS London…
Webinar: Clinical trials targeting alpha-synuclein
The latest instalment of this quarterly webinar series discussed clinical trials targeting alpha-synuclein, with Edinburgh University’s Professor Tilo Kunath as chair.
Exploring the self-image of women with Parkinson’s
There is a fundamental gap in knowledge of how Parkinson’s manifests and affects women. The Parkinson’s advocate group, PD Avengers and a collection of women living with Parkinson’s have…
Movers & Shakers: six familiar faces host podcast about living with Parkinson’s
A group of six friends living with Parkinson’s – some or all of whom you may recognise – regularly host a podcast to raise awareness of the condition. Cure…
2023: research highlights for the year ahead
Cure Parkinson’s is looking forward to an eventful 12 months – here we provide a summary of what’s on the horizon.
Research Update Meeting Spring 2023 – recorded to watch again
Our popular and much-awaited research update meeting brought together two leading clinicians to report on their individual area of expertise for Parkinson’s. It’s available to watch again!
Webinar: exercise and motivation
Presented by the Edinburgh University, Journal of Parkinson’s Disease, and Cure Parkinson’s; we are delighted to see a return of this quarterly webinar series, with Edinburgh University’s Professor Tilo…
Webinar: Embracing equity in healthcare for women with Parkinson’s
This webinar on 10 March marked International Women’s Day. It is now available to watch again.
USD $4.5 million co-funding agreement for Parkinson’s research renewed
Cure Parkinson’s and Van Andel Institute (VAI) are delighted to announce that their co-funding agreement, which supports collaborative Parkinson’s clinical trials, has been renewed for a further three years.
The role of faulty cell protein in Parkinson’s
A process called m6A mRNA methylation is reduced in people with Parkinson’s. Research is underway to develop drugs that can improve this protein production process.
New biotech company focused on cell transplantation for Parkinson’s
Biotech company Ryne Bio has received a large research grant from CIRM to develop their late-stage preclinical cell transplantation procedure for Parkinson’s.
Sun Pharma shines on c-ABL
Sun Pharma have published data on their new drug vodobatinib which is a c-ABL inhibitor – c-ABL is over-active in the brains of people with Parkinson’s.
Cure3 2023 raises almost £700,000 in most successful edition to date
Cure Parkinson’s, in association with Bonhams and Artwise, is delighted to announce that the 2023 acclaimed selling art exhibition Cure3 has raised almost £700,000 making this the most successful…
Payroll Giving Month 2023: how you can help your employees support the causes they care about
Cure Parkinson’s is pleased to announce that a large-scale phase 3 clinical trial of ambroxol, to determine whether the drug can slow the progression of Parkinson’s.
Cure Parkinson’s announces new chair of trustees
We are delighted to announce Peter Berners-Price as chair of our board of trustees.
Biotech Inhibikase develops new drug for Parkinson’s
Researchers have published laboratory data demonstrating the neuroprotective effects of a new potential drug for Parkinson’s called IkT-148009.
European Software Industry helps fund research to cure Parkinson’s
Cure Parkinson’s is delighted to announce that it has been chosen as the official charity partner to Boardwave supporting Parkinson’s research.
Cough medicine offers hope of new treatment to slow the progression of Parkinson’s disease
10 January 2023 Following promising results reported at Phase 2 in 2020, a large-scale Phase 3 clinical trial of ambroxol, a drug currently in use to treat respiratory conditions,…
Phase 3 clinical trial of ambroxol for Parkinson’s confirmed
Cure Parkinson’s is pleased to announce that a large-scale phase 3 clinical trial of ambroxol, to determine whether the drug can slow the progression of Parkinson’s.
Cure3 2023 with artists including Tracey Emin and Sir Frank Bowling
Cure Parkinson’s in association with Bonhams and Artwise are delighted to announce the fourth edition of Cure3 – the critically acclaimed selling exhibition devised to raise awareness and funds…
Year in review: 2022
At the end of each year, it is a useful process to take stock and review what we have learnt over the last 12 months. 2022 has been…
Our 2022 research summary
2022 has seen Cure Parkinson’s emerge from the COVID pandemic with a bumper year of research activity; with clinical trial results being reported and exciting, innovative research projects being…
STEM-ing the progression of Parkinson’s
An exciting new clinical trial called STEM-PD is due to start in Sweden and the UK which will focus on stem cell transplantation as a potential treatment for Parkinson’s.
Results of FAIRPARK-II deferiprone trial published
The results of the most recent study of deferiprone in people with Parkinson’s (the FAIRPARK-II study) have been published in the New England Journal of Medicine.
Cure Parkinson’s runners head across the pond for the 2022 New York City Marathon
Four inspirational runners joined Team Cure at the New York City Marathon to raise funds for Parkinson’s research. On Sunday 6 November Cure Parkinson’s CEO Will Cook, Nicky Edwards…
Cure Parkinson’s supporter tackles 100 of Britain’s toughest cycling climbs
Steve Boote cycled 3833km and climbed an astounding 69219m to raise funds and awareness for our research. Steve, a keen cyclist from Steeple Aston, recently completed Britain’s 100 greatest…
Disease modification-ish
Semantics matters – particularly regarding our communication on ideas like “disease modification” for neurodegenerative conditions. There is a big difference between “disease eradication” (zero worldwide incidence), “disease correction”…
Sport Parkinson’s Four Nations Golf Tournament returns to raise vital funds for a cure
40 golfers with Parkinson’s (and a further 40 VIP guests) took part in the two-day golfing event. The tournament was held at The Belfry Hotel in Royal Sutton Coldfield…
Our Autumn Newsletter
Download your interactive PDF copy here now!
2022 Royal Parks Half Marathon runners raise funds for Parkinson’s research
Our fantastic runners raised over £15,500 for our Parkinson’s research at this year’s Royal Parks Half Marathon 19 incredible Cure Parkinson’s supporters took part in this year’s Royal Parks…
The 2022 Grouse & Grape Luncheon raises over £28k in support of Parkinson’s research
Members of the Wealth Management sector came together for this spectacular networking event raising funds and awareness for Cure Parkinson’s. Around 200 people attended this year’s distinguished gathering held…
Cure Parkinson’s announces new role: Head of Pipeline Research
13 October 2022 Cure Parkinson’s is delighted to announce that Dr Leah Mursaleen has been appointed to the newly created role, Head of Pipeline Research. The purpose of this…
The 2022 International Linked Clinical Trials meeting
Cure Parkinson’s annually coordinates the International Linked Clinical Trials (iLCT) meeting to rank and prioritise therapies that may have the potential to modify the course of Parkinson’s progression.
Cure Parkinson’s announces new role: Head of Pipeline Research
Cure Parkinson’s is delighted to announce that Dr Leah Mursaleen has been appointed to the newly created role, Head of Pipeline Research. The purpose of this role is to…
The 2022 London Marathon raises over £127k for our Parkinson’s research
On Sunday 2 October, 32 Cure Parkinson’s supporters took part in the epic TCS London Marathon, raising £127,000 to help find a cure for Parkinson’s.
2022 Tom Isaacs Award pays tribute to Drs. Michael Okun and Ray Dorsey
Cure Parkinson’s and Van Andel Institute (VAI) are delighted to announce Dr Ray Dorsey, University of Rochester, and Dr Michael Okun, University of Florida, are joint winners of the…
2022 Tom Isaacs Award honours leading Parkinson’s researchers and co-authors of Ending Parkinson’s
Cure Parkinson’s and Van Andel Institute (VAI) are delighted to announce Dr Ray Dorsey, the David Levy Professor of Neurology at the University of Rochester, and Dr Michael Okun,…
Professor David K. Simon announced as new chair of leading Parkinson’s research committee
27 September 2022 Cure Parkinson’s and Van Andel Institute are delighted to announce that Professor David K. Simon, of Beth Israel Deaconess Medical Center and Harvard Medical School, Boston,…
Professor David K. Simon: new chair of the iLCT Committee
Cure Parkinson’s and Van Andel Institute are delighted to announce that Professor David K. Simon, of Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, United States has…
Tribute to Her Majesty The Queen
We are very saddened to hear of the death of Her Majesty Queen Elizabeth II and would like to offer our deepest condolences to The Royal Family at this…
Cycling America’s Coast to Coast to help find a cure
Kate Osborne cycled 3,659 miles from California to North Carolina to raise funds and awareness for Parkinson’s research. When Kate was planning her epic 3,659 mile cycle, she decided…
Questions about Parkinson’s: ask the expert
NIHR Clinical Research Network Thames Valley and South Midlands recorded a recent webinar featuring Professor Michele Hu and journalist Rory Cellan-Jones.
Phase 1 trial results of new GDNF delivery mechanism
The results of a recent clinical trial testing a new way of delivering the nerve growth factor, GDNF, into the brains of people with Parkinson’s demonstrate that it is…
Diet, exercise and Parkinson’s
A recently published large new study provides strong evidence that consuming a healthy diet and engaging in physical activity may improve outcomes for people with Parkinson’s.
Our Raid Alpine challengers cross the finish line, raising £150k …and still climbing!
On Saturday 9 July, our incredible team of supporters crossed the finish line of their Raid Alpine challenge, covering 770km of distance and 18,000m of ascent – all on…
Rallying to the Challenge 2022: watch again
Rallying to the Challenge is a meeting designed for and by people with Parkinson’s, advocates and care partners to explore how the Parkinson’s community can impact and accelerate research.
World Health Organisation (WHO) launches global strategy for Parkinson’s
The WHO have published a technical brief entitled Parkinson disease: a public health approach, outlining the global burden, treatment gaps and crucial areas for intervention in Parkinson’s.
22 incredible fundraisers take on gruelling Alpine cycle challenge in support of Cure Parkinson’s
On Monday 4 July, a group of 22 fundraisers will set off from the shores of Lake Geneva to take on the historic Raid Alpine cycle challenge. This gruelling…
A sub-study of azathioprine in Parkinson’s
There is increasing evidence that inflammation and the immune system might have contributory roles in the development and progression of Parkinson’s.
Raid Alpine 2022: Team take on the Alps
Setting off on 4 July, 22 dedicated challenge cyclists took on the Raid Alpine route, cycling 770 kilometres through some of the most feared climbs, to raise funds for…
Dr Simon Stott appointed to Director of Research at Cure Parkinson’s
21 June 2022 Cure Parkinson’s is pleased to announce that Dr Simon Stott, current Deputy Director of Research at Cure Parkinson’s, has been promoted to the role of Director…
The influence of diabetes on Parkinson’s progression
In recent research funded by Cure Parkinson’s, scientists have provided the strongest evidence to date that diabetes can affect the progression of Parkinson’s.
Inhibikase makes a case for c-Abl
Research has suggested that in some cases of Parkinson’s a protein called c-Abl tyrosine kinase is abnormally over-active and this contributes to nerve cell inflammation and eventual cell death….
Dr Simon Stott appointed Director of Research
Cure Parkinson’s is pleased to announce that Dr Simon Stott has been promoted to the role of Director of Research.
A million steps forward for Parkinson’s
On Tuesday 31 May, six friends from Hertfordshire crossed the finish line of their challenge of collectively walking a million steps in May, raising funds and awareness for Parkinson’s…
The 2022 Parkinson’s drug development pipeline report
The 2022 annual report, outlining the current development pipeline of new drug-based treatments for Parkinson’s, has been published.
Parkinson’s Clinical Study Group
Cure Parkinson’s is funding Professor Oliver Bandmann at the University of Sheffield to establish a nationwide infrastructure for a study group focused specifically on conducting clinical trials for Parkinson’s….
2022 Gulls’ Eggs Luncheon raises over £90k for Parkinson’s research
On Tuesday 10 May, the City’s leading wealth management professionals gathered in the historic Merchant Taylors’ Hall for the 34th annual Gulls’ Eggs Luncheon, raising over £72k for Parkinson’s research.
Phase 1a trial findings of iLCT prioritised drug, Anle138b
The findings of the phase 1a clinical trial of Anle138b have been published. Anle138b is a new drug that targets the build-up of alpha synuclein, a protein that clumps…
Our Spring Newsletter
Download your interactive PDF copy here now!
Spring Research Update Meeting 2022 – recorded to watch again
Theme: Why diabetes drugs might be an important potential line of treatment for Parkinson’s. The meeting was recorded and is available to re-watch now
New mRNA activators for Parkinson’s
Research evidence has suggested that in Parkinson’s there is some disruption to a process involved in protein production within cells. This process is known as ‘m6A mRNA methylation’, and…
The lonafarnib pre-clinical study
This research led by Professor Joe Mazzulli, will, it is hoped, give us a better understanding of how lonafarnib can reduce the build-up of the toxic protein alpha-synuclein which…
Two families take on London to Amsterdam cycle for Parkinson’s
On 27 April, the Mostyn and Postlethwaite families will be setting off from London to tackle the incredible 286 mile cycle to Amsterdam, raising much needed funds and awareness…
Cotty’s crown for Parkinson’s
We are delighted to announce the winner of our Jubilee Crown competition as 8 year old Cotty Vicary, who created this beautiful design to be used as part of…
A rising tide with liraglutide
A class of diabetes drugs called GLP-1 receptor agonists have exhibited neuroprotective properties in models of Parkinson’s, and a Phase IIb clinical trial produced encouraging. This research has…
Peter Burns and Vicky Knight announced as Fundraisers of the Year 2021
Cure Parkinson’s is delighted to announce the winner of the 2020 Fundraiser of the Year Award as the incredible Meriel Buxton. This award recognises a person who has ‘gone…
World Parkinson’s Day: Mike Tindall raises awareness on BBC Breakfast
Cure Parkinson’s patron Mike Tindall spoke to BBC Breakfast’s Sally Nugent and Jon Kay on World Parkinson’s Day about his own family’s experience of the condition and the urgent…
Peter Burns and Vicky Knight – Fundraisers of the Year 2021
Cure Parkinson’s is delighted to announce the winner of the 2020 Fundraiser of the Year Award as the incredible Meriel Buxton. This award recognises a person who has ‘gone…
Get Involved: World Parkinson’s Day 2022
11 April marks World Parkinson’s Day, the highlight of Parkinson’s Awareness Month which aims to raise greater awareness of the condition that affects around 10 million people worldwide. This…
Liraglutide trial: results
Researchers from Cedars Sinai Hospital, Los Angeles have presented their initial top line results of the liraglutide trial, co-funded by Van Andel Institute and Cure Parkinson’s, at the recent…
Liraglutide trial: results
Researchers from Cedars Sinai Hospital, Los Angeles have presented their initial top line results of the liraglutide trial, co-funded by Van Andel Institute and Cure Parkinson’s, at the recent…
Parkinson’s charity with local roots launches tree planting campaign with Micklefield Hall
Croxley founded charity Cure Parkinson’s has launched Planting for a Cure, a new campaign which will allow up to 500 trees to be planted and dedicated to those who…
Nicotinamide riboside for Parkinson’s: pilot results published
Researchers in Norway have published the promising results of a pilot clinical study of nicotinamide riboside for people with Parkinson’s.
Diabetes dual agonist drugs for Parkinson’s
Glucagon-like peptide 1 receptor (or GLP-1R) agonists are recognised as a frontline treatment for diabetes. Researchers have recently been developing the next generation of treatment for diabetes which target…
Hospitality Finder Christmas event raises over £30k for Parkinson’s research
On Thursday 2 December, Corporate entertainment company Hospitality Finder kicked off the festive season with their Green Room Live Christmas Event at The Kia Oval cricket ground, supporting Dallaglio…
GCase and Parkinson’s: a new perspective
Recently researchers have provided new insights into how small defects in a region of DNA called the GBA gene could be affecting cell biology leading to Parkinson’s.
GCase: Mutants matter?
Tiny genetic variations in a region of DNA called the GBA gene are associated with an increased risk of developing Parkinson’s. The information in the GBA gene provides…
Clinical results from Enterin trial
Biotech company Enterin has announced the results of their phase 2 clinical trial of ENT-01 indicating that it had a positive benefit on the gut symptoms associated with Parkinson’s.
Cure Parkinson’s ambassador resumes solo drive across Africa
This spring, Colonel Guy Deacon CBE will be driving an incredible 6,000 miles across Africa, from Sierra Leone to Cape Town, to raise vital awareness for Parkinson’s.
The mannitol pilot study results
The findings of a randomised, blinded clinical trial of the sweetener mannitol have been published. The results indicate that the molecule is safe and tolerable, but the study has…
The road ahead: 2022
The first post at the start of each year on the SoPD website tries to provide an overview of where things are in the search for ‘disease modifying’…
Exercise and Parkinson’s
It is a well-known fact that exercise is important for our general wellbeing. Recently, there has been a lot of new research published indicating that exercise could also potentially…
A year in review: our 2021 research funding update
Despite a challenging year caused by COVID-19, Cure Parkinson’s has not been deterred in its efforts to identify and progress novel therapies to slow, stop and reverse Parkinson’s in…
Paul Mayhew-Archer and friends present his poem ‘When Santa got Parkinson’s’
Cure Parkinson’s patron and TV comedy writer Paul Mayhew-Archer has written a wonderful poem as part of our Christmas Appeal, based on the notion that Father Christmas has Parkinson’s….
2021 Grouse & Grape Luncheon raises over £14k for Parkinson’s research
On Tuesday 7 December, over 90 guests attended the historic Cavalry and Guards Club on London’s Piccadilly for the annual Grouse & Grape Luncheon, raising over xx for Parkinson’s…
Tackling toxic alpha-synuclein
Three major lines of clinical investigation are currently underway to determine if stopping the clustering of alpha-synuclein in Parkinson’s can help to slow down the progression of the disease.
ADepTing to the UCB-Novartis deal
Alpha synuclein has long been viewed at “Public enemy #1” by the Parkinson’s research community. This sticky, abundant protein starts to cluster (or aggregate) in Parkinson’s. There have…
Sisters fundraise and raise awareness for Cure Parkinson’s
Sisters Susanna and Eliza Kidd had a super summer of fundraising for Cure Parkinson’s!
The AND-PD Trial
This study (ANxiety with or without depressive features in Parkinson’s Disease ‘AND-PD’) is an observational and imaging study where people at different stages of Parkinson’s will be assessed and…
The Anle138b Trial
This clinical trial is testing a small molecule called Anle138b to assess its potential to inhibit alpha-synuclein masses accumulating. In Parkinson’s, alpha-synuclein, which is abundant in nerve cells, begins clumping together (or aggregating) and…
PD Frontline
As research has expanded in the area of Parkinson’s genetics, researchers have been able to uncover a number of genes which have been linked to an increased risk of…
The Bydureon (exenatide) phase 3 trial
Cure Parkinson’s is delighted to be supporting two sub-studies within the Bydureon (exenatide) phase 3 trial which is recruiting from six sites in the UK. This phase 3 clinical…
The PROSEEK trial of KO706
Sun Pharma Advanced Research Company (SPARC) is conducting a phase 2 clinical trial to evaluate the safety and effectiveness of its experimental c-Abl inhibitor KO706 in people with early…
Patron Paul Mayhew-Archer raises over £10k for Cure Parkinson’s and Maggie’s Cancer Centres
Arabella Slinger from London, will set off to complete this extreme and gruelling challenge in support of Parkinson’s research.
First British woman to ski Amundsen’s route to the South Pole takes on the challenge for Cure Parkinson’s
Arabella Slinger from London, will set off to complete this extreme and gruelling challenge in support of Parkinson’s research.
NECTAR 2021
The Network for European CNS Transplantation and Restoration (NECTAR) was founded over 25 years ago. Here, Dr Simon Stott presents a brief update on the events at NECTAR 2021.
Post-hoc analyses of the isradipine and nilotinib trial results
Results from major Parkinson’s clinical trials, of the blood pressure medication isradipine and the cancer treatment nilotinib, found that these drugs had no effect on the progression of the…
Farnesol: from perfume to Parkinson’s
A ground-breaking Cure Parkinson’s supported study that involved screening over 230,000 molecules has identified farnesol, a commonly found aromatic oil, as a new potential treatment of Parkinson’s.
Is Inhibikase ‘Abl’ to beat nilotinib in treating Parkinson’s?
Inhibikase Therapeutics has designed a novel drug that is similar to the drug nilotinib – previously tested in people with Parkinson’s – but is better at reaching its target…
Cure Parkinson’s launches legacy campaign
On 27 October, 50 long-time supporters of Cure Parkinson’s gathered at Micklefield Hall in Sarratt, Hertfordshire for the launch of our legacy campaign, Planting for a Cure.
Mo better for TEVA with Modag?
This week the pharmaceutical company TEVA Pharmaceuticals Industries Ltd has announced a deal with a small German biotech firm called MODAG. The two companies are forming a…
Webinar: Deep Brain Stimulation (DBS)
Presented by the Journal of Parkinson’s Disease, Cure Parkinson’s and Van Andel Institute. In this webinar, Professor Patrik Brundin chairs a panel of experts featuring: Professor Helen Bronte-Stewart Stanford…
The Tom Isaacs Charity Golf Day 2021
On Thursday 14 October, 54 players enjoyed a round of golf in memory of Cure Parkinson’s late Co-founder and President, Tom Isaacs, raising over £2,000 for Parkinson’s research. The…
Prime Minister awards ‘Points of Light’ to our Fundraiser of the Year
Meriel Buxton, our 2020 Fundraiser of the Year, has received Prime Minister Boris Johnson’s Points of Light award.
New potential drugs for repurposing in Parkinson’s
The development of new drugs is a long and expensive process, taking many years of funding to bring new therapeutics to treat diseases. Drug repurposing offers a means of…
Repurposing bumetanide for Alzheimer’s
Bumetanide (Bumex) is a diuretic drug (a medication that removes water, by increasing the production of urine). It is used to treat swelling caused by heart failure or…
Patron Mike Tindall speaks to four families affected by Parkinson’s on BBC Breakfast with Sally Nugent
In a poignant piece for BBC Breakfast, Cure Parkinson’s patron Mike Tindall and BBC presenter Sally Nugent met with Alison Anderson, Amarpal Harrar, Omotola Thomas and David Murray, all…
‘Sport Parkinson’s Four Nations Golf Tournament’ tees off at The Belfry
From 11-13 October, four teams of golfers who have Parkinson’s, from the four UK nations, will tee off on The Belfry’s Brabazon course for two days of friendly competition…
Making a (G)case for quetiapine
Drug repurposing (repositioning, reprofiling or re-tasking) is a strategy of identifying novel uses for clinically approved (or experimental) drugs that fall outside the scope of the original medical…
2021 Tom Isaacs Award honours leading Parkinson’s expert: Dr Camille Carroll
Cure Parkinson’s and Van Andel Institute (VAI) are delighted to announce Dr Camille Carroll, Associate Professor in Neurology at University of Plymouth, as this year’s deserving winner of the…
2021 Tom Isaacs Award honours Dr Camille Carroll
Cure Parkinson’s and Van Andel Institute (VAI) are delighted to announce Dr Camille Carroll, Associate Professor in Neurology at University of Plymouth, as this year’s deserving winner of the…
Webinar: Rallying to the Challenge Meeting 2021
‘Rallying to the Challenge’ is a meeting designed for and by people with Parkinson’s, advocates and care partners to explore how the Parkinson’s community can impact and accelerate research….
London Marathon 2021 raises over £80k for Parkinson’s research
On Sunday 3 October, 38 Cure Parkinson’s supporters came together to take part in the iconic Virgin Money London Marathon, raising awareness and over £80,000 for Parkinson’s research. This…
The 2021 International Linked Clinical Trials Meeting
The International Linked Clinical Trials (iLCT) programme is the flagship drug repurposing initiative of Cure Parkinson’s and Van Andel Institute (VAI) focussed on identifying and clinically testing already available drugs…
2021 Gulls’ Eggs Luncheon raises over £60k for Parkinson’s research
On Tuesday 28 September, over 300 of the City’s leading wealth management professionals gathered in the historic Drapers Hall on London’s Throgmorton Avenue for the 33rd annual Gulls’ Eggs…
Our virtual Rallying to The Challenge Meeting – ‘When and How Does Parkinson’s Begin?’
For the first time, this year’s meeting for people with Parkinson’s, was held online and focussed on the origins and development of Parkinson’s, including triggers, early symptoms and stages…
Results from the Inosine SURE-PD clinical trial
The results of a large clinical trial, of 300 individuals, of the dietary supplement ‘inosine’ have shown that the treatment had no effect on slowing the progression of Parkinson’s….
Neurotrophic Factor GDF5 – an alternative to GDNF?
Neurotrophic factors are small protein that are naturally produced in the brain to help nurture and protect nerve cells (neurons). Cure Parkinson’s is a strong supporter of research…
Recorded: Rallying to the Challenge Online Patient Meeting ‘GBA1 and LRRK2 – from genetic risk to the clinic’
Each year the Rallying to the Challenge meeting takes an aspect of Parkinson’s research and discusses how people living with the condition can support and influence work in this…
An Evening with Paul Mayhew-Archer
We’re delighted to announce that Cure Parkinson’s patron, co-writer of The Vicar of Dibley and comedic legend Paul Mayhew-Archer is back performing his stand-up show, ‘An Incurable Optimist’ with…
The Big Splash for Parkinson’s: Positively Parkinson’s swimmers cross the Solent and raise over £39,000
On Sunday 5 September, Peter Burns and Vicky Knight along with ten other swimmers, three of whom are living with Parkinson’s, took on the huge challenge of swimming 5km…
NECTAR 2021
This event brought together scientists, clinicians, patient advocates and industry partners from across Europe and the international community to share the latest research in repairing the damage to the…
The clinical trials pipeline for Parkinson’s: 2020/21
Despite the difficulties throughout 2020, a significant amount of clinical trial activity for Parkinson’s was conducted and a new report – involving the research team at Cure Parkinson’s -…
Farnesol: The farnesylator of PARIS
A build up of “PARkin Interacting Substrate” (or PARIS) protein has been proposed as one potential mediator of the pathology observed in some cases of Parkinson’s. The accumulation…
The Henley Mermaids take on the Bristol Channel
On 20 July, Laura Reineke, Jo Robb, Fiona Print, Susan Barry and Joan Fennelly, otherwise known as the Henley Mermaids, swam 61km across the Bristol Channel in support of…
The Bluerockers have started
On the 8th June, BlueRock Therapeutics put out a press release announcing that the first participant in their Phase I clinical trial of cell transplantation for Parkinson’s had…
Daisy Doyle plants 50 oak trees for Parkinson’s research
Last Autumn, 11 year old Daisy Doyle, granddaughter of Cure Parkinson’s co-founder Air Vice Marshal Michael Dicken and Patron Jenny Dicken, planted 50 oak trees on her family farm…
Cure Parkinson’s Raid Local 2021
On Sunday 27 June over 300 Cure Parkinson’s supporters from across the world jumped in the saddle to take on the charity’s Raid Local 2021: Ventoux! cycling challenge, raising…
Encouraging trial results from Anavex
Recent positive results from biotech company Anavex Life Sciences have shown that when treated with their experimental drug, blarcamesine, individuals with Parkinson’s dementia had significant improvements in both motor…
The Anavex results
This week some encouraging clinical trial results were announced by a biotech firm called Anavex Life Sciences. The company had been testing their lead experimental therapy – a…
EJS-ACT PD
This week an announcement was made regarding The Edmond J. Safra Accelerating Clinical Treatments for Parkinson’s Disease (EJS-ACT PD) Initiative. It is hoping to revolutionise the way clinical…
Improving Parkinson’s Trials: A Delphi Study
Under the visionary leadership of Dr Camille Carroll at the University of Plymouth, Cure Parkinson’s has been supporting an exploratory study at the University of Plymouth to understand the…
Team 144 walk historic bus route for Cure Parkinson’s
A team of incredible supporters from Bromsgrove has taken on the 25-mile long, locally iconic 144 bus route on foot. They have raised over £1950 for our research into…
Cure Parkinson’s Patron Mike Tindall and Trustee Lyndsey Isaacs on BBC Breakfast
In this poignant film created by BBC Breakfast, which aired on 16 April, Mike Tindall spoke openly with his parents about how his father Philip’s Parkinson’s diagnosis has impacted…
Cure Parkinson’s Cure Collective is three years old
The Cure Collective is a group of like-minded individuals committed to help drive forward the quest to find a cure for Parkinson’s. Each member pledges to support Cure Parkinson’s…
Webinar – Genetic markers and the progression of Parkinson’s
Presented by the Journal of Parkinson’s Disease, Cure Parkinson’s and Van Andel Institute. This webinar discusses recent publications around the theme of genetic markers and the progression of Parkinson’s….
Further funding announced for clinical studies and data investigation
After a year of disruption, clinical research has now restarted and lab-based research is getting back on track. Cure Parkinson’s is delighted to report that it is investing significant…
An important ruling for aducanumab
On the 7th June, the US FDA held a special meeting and approved an experimental drug called aducanumab for the treatment of Alzheimer’s. This decision represents a major milestone…
Cure Parkinson’s funds new nerve growth factors for Parkinson’s
Nerve growth or neurotrophic factors such as CDNF and GDNF are proteins that support neurons and encourage their growth and survival during development. There has been considerable preclinical research…
The exenatide phase 3 study protocol
Researchers conducting the phase 3 ‘Exenatide PD3’ clinical trial have published the protocol of the study, which outlines the details of the trial. Cure Parkinson’s is supporting two sub-studies…
Eric Mytton and Dom Kelly Run the West Highland Way for Cure Parkinson’s
From 23-27 May, Eric Mytton and his good friend Dom Kelly took on the amazing challenge of running the iconic West Highland Way in Scotland in support of Cure…
Anle138b to target the toxic protein in Parkinson’s
In Parkinson’s, a cell protein called alpha-synuclein, which is abundant in dopamine-producing nerve cells, is known to clump together (or aggregate) and it is believed that this process could…
Unmasking LRRK2 and GBA
Connecting genetics and biology is complicated. Researchers around the world have struggled to determine what each functional region of DNA is doing individually, let alone in combination with…
Joyce Cook walks over 300,000 steps for Cure Parkinson’s
On Monday 10 May, 86 year old Joyce Cook from Chorleywood crossed the finish line of her incredible 300,000 step challenge. To mark Parkinson’s Awareness Month, Joyce walked more…
Something ‘LRRK -ing’ in the data
Over recent years, researchers have been identifying genetic variations associated with an increased risk of developing Parkinson’s. A recent study has thrown further light on the connection between certain…
Joyce Cook walks over 300,000 steps for Cure Parkinson’s
86 year old Chorleywood resident completes 300,000 step challenge for Parkinson’s On Monday 10 May, 86 year old Joyce Cook from Chorleywood crossed the finish line of her incredible…
Further support for diabetes treatments for Parkinson’s
A research group in South Korea has published results of their trial which provide further evidence that diabetes treatments can slow down the development of Parkinson’s in people with…
Important phase 1 trial results for LRRK2 inhibitor drug
This week the biotech company Denali Therapeutics announced the results of a phase 1 clinical trial of their LRRK2 inhibitor drug called ‘DNL151’. Their findings have interesting implications for…
The Virtual Royal Parks Half 2021
On Sunday 11 April, Cure Parkinson’s supporters François Berrier, Sharon Dawson, Vonnie Newton, Tammy Kustow, Jon Sellen and Natalie Gedra took part in the Virtual Royal Parks Half Marathon….
Documentary: ‘The Parkinson’s Drug Trial: A Miracle Cure?’
This award winning documentary was first broadcast in 2019 and features trial participants, including our late co-founder Tom Isaacs, in a cutting-edge drug trial involving complex brain surgery; and…
The Duchess of Gloucester and Mike Tindall mark Parkinson’s Awareness Month
April marks World Parkinson’s Awareness Month to highlight the condition that affects some seven to 10 million people globally. At the centre of this month is World Parkinson’s Day…
The Great Big Comedy Quiz
Last Thursday, over 100 teams came together on Zoom to take part in The Great Big Comedy Quiz, hosted by legendary comedian Tim Vine and TV comedy writer and…
UCB at ANN looks A-OK
Alpha synuclein is one of the most common proteins in our brains and it has long been associated with Parkinson’s. The protein appears to clump together forming dense…
Jane Birkin’s 5-50-500 TRYathlon Challenge
On 5 May, Cure Parkinson’s supporter Jane Birkin will begin her 5-50-500 TRYathlon, a fundraising challenge she created to mark her 50th birthday!
PD Avengers webinar hosted by Cure Parkinson’s: Women with Parkinson’s
Can meeting the needs of women living with Parkinson’s unlock new treatments to better manage, slow, stop or even cure Parkinson’s? Re-watch our recent webinar.
Iron and the brain
Recent studies exploring iron levels in the brains of people with Parkinson’s have shown important implications for its use as a biomarker, as well as a way of potentially…
Meriel Buxton announced as Cure Parkinson’s Fundraiser of the Year 2020
Cure Parkinson’s is delighted to announce the winner of the 2020 Fundraiser of the Year Award as the incredible Meriel Buxton. This award recognises a person who has ‘gone…
Meriel Buxton – Fundraiser of the Year 2020
Cure Parkinson’s is delighted to announce the winner of the 2020 Fundraiser of the Year Award as the incredible Meriel Buxton. This award recognises a person who has ‘gone…
World Parkinson’s Day
April marks World Parkinson’s Awareness Month to highlight the condition that affects some seven to 10 million people globally. At the centre of this month is World Parkinson’s Day…
iLCT provides template for drug repurposing in other conditions
The International Linked Clinical Trials programme (iLCT) is one of the largest drug repurposing initiatives in medical research. A recent review article provides an overview of the history, structure…
Van Andel Institute: Virtual public lecture series
This informative event featured presentations and a Q&A session with international Parkinson’s disease experts including Cure Parkinson’s Director of Research, Dr Richard Wyse and Deputy Director of Research, Dr…
A skin test for Parkinson’s
Researchers have been investigating a waxy substance on our skin (called sebum) as a possible way of determining who does or does not have Parkinson’s.
What is GDNF without RET?
Neurotrophic factors – like Glial cell line-derived neurotrophic factor (or GDNF) – hold great hope for regenerative therapy in Parkinson’s research. New research, however, indicates that simply injecting…
Results of the MOVES-PD trial announced
MOVES-PD is a global phase 2 study to assess the efficacy and safety of the drug venglustat in Parkinson’s patients who have a GBA-1 gene mutation. Sanofi designed the…
Further data on the relationship between diabetes and Parkinson’s
New research has found that there is convincing evidence that Type 2 diabetes is associated with a greater risk of Parkinson’s, but may in turn allow for better management…
Rheumatoid arthritis and Parkinson’s
Recently, researchers have asked whether there is an association between Parkinson’s and rheumatoid arthritis: Could people with rheumatoid arthritis be at higher risk of developing Parkinson’s?
COVID-19 and the need for remote clinical trials
Whilst the COVID pandemic has dealt a cruel blow to current Parkinson’s research efforts, it has served as an opportunity for innovation and improvement, and this is particularly so…
More data from the ‘Blue Rockers’
BlueRock Therapeutics has published two preclinical research reports outlining the cell culturing method that they are taking into clinical trials.
Parkinson’s and pesticides
Much of our focus is on treatments, but treatments are only part of the story. A vital step for Cure Parkinson’s is to stop people from getting Parkinson’s in…
GDNF – A new chapter
We welcome the news of further investment in GDNF (Glial Cell-Line Derived Neurotrophic Factor) by Parkinson’s UK.
Ambroxol – new real-world data
Ambroxol is a cough medication that Cure Parkinson’s is repurposing for potential use in treating Parkinson’s, and recently published data provides further support for this pioneering new study.
Cure Parkinson’s approves funding for new iron removing drug
Cure Parkinson’s continues to champion iron chelation for Parkinson’s. Trustees have now awarded a grant to develop the next generation of iron reducing drugs.
Webinar – Young Onset Parkinson’s
Presented by the Journal of Parkinson’s Disease, Cure Parkinson’s and Van Andel Institute. The latest instalment of our interactive webinar series, in partnership with The Journal of Parkinson’s Disease…
Pam Willis raises over £16,000 for Cure Parkinson’s!
We are delighted to announce long term supporter and friend of Cure Parkinson’s Pam Willis has raised over £16,000 for our ground-breaking research since she began fundraising for the…
Gut feeling about bile acids
Researchers have reported that the ability of gut bacteria to break down fat is disrupted in people with Parkinson’s, resulting in issues with the production of bile acid.
Positioning prostate drugs for Parkinson’s
Researchers have published evidence that a class of drugs commonly used for the treatment of prostate enlargement may have beneficial properties for Parkinson’s.
Trying to LIMP-2 the lysosome
Lysosomes are small bags of enzymes that are used to break down material inside of cells – digesting newly absorbed food or recycling old/used proteins and rubbish. Recently…
Post-hoc analysis of steady-PD3 trial results
Recent post-hoc analysis of the Steady-PD3 trial data has highlighted some interesting effects.
‘AskBio’ acquires BNB and GDNF gene therapy trials
BNB and AskBio have joined forces to expand a gene therapy programme for Parkinson’s
The Road Ahead: 2021
At the start of each year, it is a useful practise to layout what is planned over the next 12 months. The events that are scheduled for the…
DROPS UCI vs. Tindall & Co: Chase! In aid of Cure Parkinson’s
On 16 January, over 800 riders from across the globe took to their turbo trainer bikes at home and joined the epic DROPS UCI vs. Tindall & Co: Chase,…
Webinar – Coronavirus and Parkinson’s
Presented by the Journal of Parkinson’s Disease, Cure Parkinson’s and Van Andel Institute. This webinar discusses recent publications about Coronavirus and Parkinson’s. The eminent panel, once again chaired by…
The need for novel c-Abl inhibitors
A protein called Abelson Tyrosine Kinase – or c-Abl – is believed to be involved in the biological processes leading to loss of dopamine neurons in the brains of people with Parkinson’s. In…
The AIM-PD trial (ambroxol)
Supported and funded by Cure Parkinson’s, Van Andel Institute and the John Black Foundation, the next phase of this trial programme will follow shortly. Phase 2 of the ‘AIM-PD’…
The UP-Study trial (UDCA)
This trial is now complete. Supported by Cure Parkinson’s and the J P Moulton Foundation, the results are expected in 2021. Originally used to treat cirrhosis of the…
TGF-beta: The Parkinson’s superfamily?
A lot of Parkinson’s research has focused on a neurotrophic factor called glial cell-derived neurotrophic factor (or GDNF). But GDNF only represents a small fraction of a much…
Cell Replacement Therapy – TRANSEURO
TRANSEURO, involving a consortium of scientists led by Professor Roger Barker in Cambridge and funded in part by Cure Parkinson’s and the EU, has developed a clear pathway to…
The drug development pipeline for Parkinson’s
For a long time a regular request from SoPD readers has been to provide an overview of the clinical trial landscape for Parkinson’s, particularly in the area of…
Kit Noble cycles from John O’Groats to Land’s End for Parkinson’s
Supporter Kit Noble recently set off on his bike to begin the immense challenge of cycling from John O’Groats to Land’s End in a bid to raise awareness and…
Alex Green runs 102 miles for Parkinson’s research!
On the weekend of the 4 and 5 September, Cure Parkinson’s supporter Alex Green (pictured below) took on the fantastic challenge of running 102 miles of the Cotswold Way…
A triathlon challenge for tri-ing times!
Cure Parkinson’s would like to say a huge thank you to supporters Georgie and Matt (pictured below), who completed their incredible challenge of running, cycling and swimming the equivalent…
The Ricky Road Run goes virtual for 2020!
From Friday 17 July – Monday 3 August, 30 running enthusiasts took part in the ‘virtual’ Ricky Road Run in support of Cure Parkinson’s pioneering Parkinson’s research. Due to…
A cycle challenge turns virtual for Parkinson’s research
This summer supporters Vivienne & Alec Armitage along with a team of family and friends including their daughter and son in law Rosie and Peter Ward were due to…
Further support for GLP-1R agonists
Glucagon-like peptide 1 receptor (or GLP-1R) agonists are a frontline treatment for diabetes – improving glycaemic control by reducing glucose concentrations in the blood. In 2008, multiple research…
Further support for GLP-1R agonists
Glucagon-like peptide 1 receptor (or GLP-1R) agonists are a frontline treatment for diabetes – improving glycaemic control by reducing glucose concentrations in the blood. In 2008, multiple research…
Joe Gregory’s 10,000 keepy-uppy’s for Cure Parkinson’s
Earlier this year, supporter Joe Gregory set himself the challenge of completing 10,000 consecutive keepy-uppy’s. Attempting to achieve his goal throughout April (Parkinsons Awareness Month), Joe managed to complete…
Who’s the most ‘Hintelligent’? Hinterview hold charity quiz night for Cure Parkinson’s
On 6 February, 150 recruitment professionals gathered together at Morton Society in London in the name of charity to compete in the annual ‘Hintelligence’ quiz night, hosted by virtual…
Ann Winter Walks Isle of Wight Coastal Path for Cure Parkinson’s
On Friday 17 January, Ann Winter began her magnificent journey, walking 70 miles along the Isle of Wight Coastal path to raise funds and awareness for Cure Parkinson’s. She…
Elizabeth Day runs New York Marathon for Cure Parkinson’s
Last year Cure Parkinson’s supporter Elizabeth Day (pictured below) took on the magnificent New York Marathon on 3 November to raise funds for our pioneering Parkinson’s research. Elizabeth was…
Paul Mayhew-Archer MBE becomes a Patron
We are delighted to announce that TV writer, producer and comedian Paul Mayhew-Archer MBE is now a patron of The Cure Parkinson’s Trust (CPT). The co-writer of The Vicar…
Paul Mayhew-Archer MBE announced as Patron
Writer, producer, script editor and comedian Paul Mayhew-Archer receives MBE for services to Parkinson’s and cancer, and announces Patronage of The Cure Parkinson’s Trust
‘Barnesy’s’ Biography for Parkinson’s
Cure Parkinson’s would like to say a huge thank you to the inspirational Robert Barnes- known as ‘Barnesy’ by those closest to him- who has taken the time to…
Type 2 diabetes medications impact risk of Parkinson’s
In a recent study, researchers have concluded that the elevated risk of Parkinson’s in patients with type 2 diabetes might be mitigated depending on the type of drugs prescribed…
The 2020 International Linked Clinical Trials meeting
The International Linked Clinical Trials (iLCT) programme is the drug repurposing initiative focussed on identifying and clinically testing drugs that show potential in slowing or reversing the progression of…
The 2020 Linked Clinical Trials meeting
Each year in September, The Cure Parkinson’s Trust and Van Andel Institute hold the international Linked Clinical Trials (iLCT) meeting. This is a drug-repurposing initiative focused on disease…
2020 Tom Isaacs Award honours leading Parkinson’s expert
25 September 2020 The Cure Parkinson’s Trust (CPT) and Van Andel Institute (VAI) are delighted to announce Professor Caroline Tanner of University of California San Francisco’s Weill Institute for…
International Linked Clinical Trials strategic funding for Parkinson’s now worth US$6.75 million
LONDON (21 September, 2020) The Cure Parkinson’s Trust (CPT) and Van Andel Institute (VAI) are delighted to welcome a third strategic funding partner, The John Black Charitable Foundation (JBCF),…
The John Black Charitable Foundation joins Cure Parkinson’s as Strategic funding partner
Cure Parkinson’s and Van Andel Institute (VAI) are delighted to welcome a third strategic funding partner, The John Black Charitable Foundation (JBCF), to the International Linked Clinical Trials (iLCT)…
Drug shows signs of efficacy in early stage Parkinson’s
A protein called alpha-synuclein builds up in the brains of people with Parkinson’s. This accumulation is believed to play a role in the progressive nature of Parkinson’s.
The PD-STAT/Simvastatin study results
Why is this important? In 2012, an international committee of Parkinson’s experts brought together by Cure Parkinson’s prioritised simvastatin for clinical evaluation in Parkinson’s. The International Linked Clinical Trials…
Dexamethasone for COVID – and perhaps Parkinson’s?
Recent studies screening medical record databases suggest anti-inflammatory drugs like dexamethasone may reduce the risk of developing Parkinson’s.
Webinar – Prodromal Parkinson’s
Presented by the Journal of Parkinson’s Disease, Cure Parkinson’s and Van Andel Institute. Prodromal Parkinson’s is the stage at which individuals exhibit signs and symptoms that indicate a higher…
A biomarker for Parkinson’s?
A research report published this week, highlights a protein that could represent the first ‘biomarker’ for Parkinson’s progression.
The epigenetics of Parkinson’s.
Researchers at the Van Andel Institute in Grand Rapids (Michigan) have identified a “master regulator” gene switch that may protect the brain from neurodegenerative processes associated with Parkinson’s.
DENALI and Biogen team up against LRRK2
The biotech company Denali have announced that they have signed a collaborative deal with the pharmaceutical company Biogen.
MODAG: positive phase 1 results of potential new Parkinson’s drug
Supported by Cure Parkinson’s, German Biotech company MODAG have announced positive results from their phase 1 clinical trial of Anle138b for Parkinson’s.
An overview of drug development for Parkinson’s
A recently published research report conducted by Parkinson’s research advocates and Cure Parkinson’s presents an encouraging overview of pipeline agents being clinically tested for Parkinson’s.
Dr Richard Wyse co-edits prestigious Cochrane Report
Cure Parkinson’s is honoured that our Director of Research, Dr Richard Wyse is co-editor of a new Cochrane Report titled ‘GLP‐1 receptor agonists for Parkinson’s disease’.
Further evidence of neuroprotection of simvastatin in Parkinson’s
Foundation, researchers have concluded that the elevated risk of Parkinson’s disease in patients with type ll diabetes might be mitigated depending on the type of drugs prescribed to treat…
The liraglutide trial for people with Parkinson’s
This clinical trial will test the efficacy and safety of the diabetes drug liraglutide (a GLP-1 agonist) in people with Parkinson’s. The trial is taking place at the Cedars-Sinai…
Blood plasma infusions for Parkinson’s
Blood plasma may have beneficial effects in neurodegenerative conditions, including Parkinson’s.
Parkinson’s: The absence of appendixes and tonsils
Researchers in Stockholm have recently published a report indicating that the removal of the appendix or tonsils could reduce a person’s risk of developing Parkinson’s.
The Cure Parkinson’s Trust’s BBC Radio 4 Appeal raises over £108,000
1 July 2020 The Cure Parkinson’s Trust’s BBC Radio 4 Appeal, which aired on Sunday 12th April, has raised a staggering £108,335.75 (including Gift Aid). This is one of…
The Raid Local Cycle Challenge 2020
On Sunday 28 June, over 1,000 supporters of Cure Parkinson’s took to the saddle to take part in the charity’s ‘Raid Local‘ cycle challenge, the first of our multi-participation…
Welcome to the Jersey of Hope 2020
Cure Parkinson’s is delighted to announce that Performance Cycling Apparel company ‘Le Col’ have generously designed and made a limited number of cycling jerseys following Cure Parkinson’s virtual Raid…
Astrocytes to dopamine neurons in one step
The brain is made up of multiple types of cells. There are the neurons that conduct much of the cognitive functioning in the brain, Then there are a collection…
Our ‘Raid Alpine’ has become ‘Raid Local’. Join us!
This June, 44 supporters of CPT were due to take on the legendary Raid Alpine. As this event has been postponed due to COVID-19 restrictions, CPT has launched in…
GBA: Wider regulation = wider implications
Tiny variations our DNA can have a significant impact on our lives. For the last 20 years, Parkinson’s researchers have been collecting data highlighting ‘genetic risk factors’ that…
Mike Tindall unites with fellow sporting legends for Raid Local
Mike Tindall leads team of British sporting legends including Sir Chris Hoy, Shane Williams, Amy Williams, Austin Healey, Iain Balshaw, Lee Westwood & Kirsty Gallacher in cycle race for…
Phase 1 results for a Parkinson’s vaccine
Austrian biotech company AFFiRiS have published the results of their phase l clinical trial testing the safety and tolerability of a vaccine treatment for Parkinson’s.
A greater role for the parkinson’s GBA gene protein?
There is a great deal of variability between each person affected by Parkinson’s. Better knowledge of these variables could not only provide insights into the underlying biology of…
Cure3 Announced – 80 leading artists and fashion designers unite for a selling exhibition in aid of The Cure Parkinson’s Trust
11 June 2020 The Cure Parkinson’s Trust, in association with Bonhams and Artwise, is delighted to announce Cure3 2020, the 3rd edition of the acclaimed selling exhibition devised to…
Webinar – Neurotrophic Factors and Parkinson’s
Presented by the Journal of Parkinson’s Disease, Cure Parkinson’s and Van Andel Institute. The panel of experts include: Chair – Prof Patrik Brundin, Dr. Howard Federoff – Professor of…
PDCORE
Assessing the progression of Parkinson’s is a very difficult task, but accurately doing so is critical to our ability to evaluate the disease modifying potential of new therapies….
MAMS the word
The way that clinical trials are conducted doesn’t make much sense. They take too long and a lot of resources to set up, they take a long time…
MAMS the word
The way that clinical trials are conducted doesn’t make much sense. They take too long and a lot of resources to set up, they take a long time…
Multi-Arm Multi-Stage – a new approach to clinical trials
One of the most frustrating aspects of clinical trials is the long delays between studies. Dr Camille Carroll is leading a group of researchers exploring the use of multi-arm…
The 2021 Gulls’ Eggs Luncheon
Today (11 May) would have been the 33rd Annual Gulls’ Eggs Luncheon in support of Cure Parkinson’s. It will now be taking place physically at Merchant Taylors’ Hall on…
Fox Insight launches COVID-19 survey
Fox Insight, the online Parkinson’s clinical study, have launched their ‘COVID study’ designed to capture experiences from people with and without Parkinson’s disease. With little research being carried out…
Maura Ward – Fundraiser of the Year 2019
Fundraiser of the Year 2019 The Fundraiser of the Year Award recognises an individual who has ‘gone above and beyond’ to raise funds and/or awareness for Parkinson’s. This year…
The STEADY-PD trial results
The results of the Phase lll STEADY-PD clinical trial have now been published.
A better delivery of Dopamine
People with Parkinson’s have a severe reduction in levels of a protein called dopamine in their brains. Lower levels of dopamine are associated with the motor symptoms of the…
3P: Parkinson Postdoc Program Seminars
Cure Parkinson’s, Van Andel Institute and World Parkinson Coalition Institute present: The 3P Parkinson Postdoc Program Seminars
Time to re-nurture neurturin?
A new research report suggests that a disappointing gene therapy treatment did have an effect inside the brain, which could now have important implications for future gene therapy trials.
Exenatide: further studies initiated
In 2012, Cure Parkinson’s initiated the International Linked Clinical Trials (iLCT) programme to focus on identifying and prioritising potentially disease-modifying therapies for Parkinson’s. The first drug to be prioritised…
Multi-Arm Multi-Stage trials for Parkinson’s
At present, most clinical trials for Parkinson’s involve a single therapy, being tested against a ‘placebo’ or control treatment for a fixed period of time. At the end of…
The STEADY-PD Trial Results
Cure Parkinson’s recently approved funding for a project with Associate Professor Antony Cooper, Garvan Institute, Sydney. The project aimed to determine if there is a group of people with…
Revising our approach to treating Parkinson’s
The Krembil Knowledge Gaps in Parkinson’s Disease Symposium held in Toronto in April 2019 addressed some of the fundamental questions for further advancing Parkinson’s research. Key among the topics for discussion…
Herantis Pharma: Phase 1/2 CDNF topline results
We are delighted that Finnish-based Herantis Pharma Plc have announced that their ongoing phase 1-2 clinical trial testing the neuroprotective agent ‘cerebral dopamine neurotrophic factor’ (or CDNF) in people…
Earlier diagnosis and treatment of Dementia in Parkinson’s
A research team at the UCL Queen Square Institute of Neurology – led by Dr Rimona Weil – has recently published research that suggests the monitoring of levels of…
UDCA and laboratory cell-based Parkinson’s
There is a great deal of variability between individuals with Parkinson’s in terms of features like symptoms and speed of disease progression. Given these differences, many researchers believe that…
The Minnesota UDCA clinical study
Researchers in Minnesota (USA) have recently published the results of a small pilot clinical trial investigating the safety of Ursodeoxycholic acid (or UDCA) in Parkinson’s. Currently UDCA is used…
GDNF and cell transplantation: dual therapies for Parkinson’s
Parkinson’s is a complex condition and it is becoming increasingly clear that the future of disease-modifying therapies for Parkinson’s will rely on the use of multiple treatment approaches, as…
Similarities between Alzheimer’s and Parkinson’s
Recently, two research groups independently published journal articles suggesting that a genetic variation associated with Alzheimer’s might also have an important influence in Parkinson’s and related conditions. The scientists…
New developments in diabetes drugs for Parkinson’s
At the forefront of treatments for diabetes is a class of drug called glucagon-like peptide 1 receptor (or GLP-1R) agonists. There is also now considerable laboratory research that suggests GLP-1R diabetes…
The Ambroxol Results
The new year has started with some pleasing clinical trial news for the Parkinson’s community: The results of the “Ambroxol in Disease Modification in Parkinson Disease” (AiM-PD study)…
The Bydureon phase 3 trial: supplementary substudies
Cure Parkinson’s and Van Andel Institute (VAI) are delighted to be supporting two sub-studies within the important Bydureon phase 3 trial (Exenatide-PD 3)
Ambroxol in Parkinson’s: results of phase 2 trial published
Cure Parkinson’s, in partnership with Van Andel Institute and the John Black Charitable Foundation, is proud to announce the publication of the results of the phase 2 clinical trial…
Phase 2 respiratory drug for Parkinson’s has promise
13 January 2020 Results published today in The Journal of the American Medical Association (JAMA) Neurology Cure Parkinson’s is delighted to announce the publication of the results of a…
Cure Parkinson’s – 15 Years
2020 is a milestone year for Cure Parkinson’s. It marks our 15th year of investing in pioneering Parkinson’s research and a chance to reflect on the advances we have…
Webinar – Exercise and Parkinson’s
Presented by the Journal of Parkinson’s Disease, Cure Parkinson’s and Van Andel Institute. Re-watch our webinar discussing recent publications around the theme of exercise in Parkinson’s. The panel, once…
IPDGC 2019: London
The International Parkinson Disease Genomics Consortium (IPDGC) held their annual meeting in London in December. Over 150 researchers working on the genetics of Parkinson’s attended the two-day event which…
Clinical trial for Anle138b
The German biotech company, MODAG, announced that their first drug candidate for neurodegenerative conditions has started phase I safety testing in humans. The drug, Anle138b, is being developed for…
Keeping Pace with LRRK2 and GCase
There are a number of genetic variations that can increase one’s risk of developing Parkinson’s. Two of the most common genetic variations or mutations occur in regions of human…
GP2: global Parkinson’s genetics program
In almost every cell of a human body, genetic material or DNA is translated into proteins, referred to as genes. These genes provide the instructions for making and maintaining…
Genetic manipulators of Alpha Synuclein
In the brains of people with Parkinson’s, there is an accumulation of alpha synuclein protein. It clusters and aggregates together forming dense circular objects inside neurons called Lewy bodies….
Accelerating Medicines Partnership for Parkinson’s – AMP-PD
The US National Institute of Health (NIH) have recently announced the opening of a vast new data portal for Parkinson’s research. It is part of the Accelerating Medicines Partnership…
Ambroxol: Further validation for potential in Parkinson’s
Small variations in DNA are associated with approximately 1 in 5 of Parkinson’s cases. One of the most common genetic risk factors of developing Parkinson’s occurs in a region of…
An exercise in expectations: Exenatide III
In August 2017, the results of a Phase II double-blind, placebo controlled clinical trial investigating whether the diabetes drug Exenatide (aka Bydureon) can be repurposed for the treatment…
Webinar – Dyskinesia in Parkinson’s
Presented by the Journal of Parkinson’s Disease, Cure Parkinson’s and Van Andel Institute. Chair Professor Patrik Brundin is joined by fellow panellists Professor Ray Chaudhuri from Kings College London,…
MIRO – A new biomarker for Parkinson’s?
Researchers at Stanford University in the US looking for new biomarkers of Parkinson’s, recently identified a protein called MIRO that in initial data very accurately identifies people with the…
Tom Isaacs Award winner 2019 – Dr Tilo Kunath
Cure Parkinson’s and Van Andel Research Institute (VAI) have announced Dr. Tilo Kunath as the deserving 2019 winner of the ‘Tom Isaacs Award’. The nominations for the award this…
Phase 2 clinical trial to explore experimental K0706 in early Parkinson’s
Sun Pharma Advanced Research Company (SPARC) is conducting a phase 2 clinical trial to evaluate the safety and effectiveness of its experimental c-Abl inhibitor K0706 in people with early…
‘Voyager’ recruits patients for phase 2 gene therapy delivery
Voyager Therapeutics recently announced it is recruiting participants for the company’s phase 2 clinical trial testing the safety and effectiveness of the gene therapy VY-AADC02 in people with advanced…
Evidence that Parkinson’s originates in the gut
A new study published in the journal ‘Neuron’ has found more evidence that Parkinson’s starts in the gut
The rationale for the TRANSEURO study
The TRANSEURO study is part-funded by Cure Parkinson’s and is investigating dopamine cell replacement therapy as a restorative treatment for people with Parkinson’s. It is being coordinated by Professor…
The appendix and Parkinson’s
Although its exact role isn’t yet clear because findings have been conflicting, in this easy-to-read overview the link between the appendix in the gut and risk of developing Parkinson’s…
Webinar – Stem Cell (Cell Replacement) Therapy
Presented by the Journal of Parkinson’s Disease, Cure Parkinson’s and Van Andel Institute. This quarterly webinar series, brought to you by The Journal of Parkinson’s Disease, Cure Parkinson’s and…
The AEGIS Coast to Coast to Cure Challenge
13 supporters of Cure Parkinson’s, including Patron Mike Tindall and fellow Rugby World Cup winner Iain Balshaw MBE, recently completed the historic ‘Raid Pyrenean’ cycle challenge to raise vital…
The Coast to Coast to Cure endurance cycle
This week AEGIS London and Cure Parkinson’s hosted a Q&A event with rugby legends Mike Tindall and Iain Balshaw MBE to talk about Cure Parkinson’s ground-breaking research and the…
Remembering Tom
On 31st May in 2017, Tom Isaacs – one of the co-founder of the the Cure Parkinson’s Trust – passed away suddenly. It was a terrible shock for…
The Mike Tindall Celebrity Golf Classic 2019
We are very grateful to Mike and Zara Tindall for generously supporting this wonderful day of golf and entertainment again in aid of Cure Parkinson’s
Tim Daber – Fundraiser of the Year 2018
Fundraiser of the Year 2018 The Fundraiser of the Year Award recognises the individual who has ‘gone above and beyond’ to raise funds and/or awareness for Parkinson’s. This year…
Webinar – Sleep and Parkinson’s
Presented by the Journal of Parkinson’s Disease, Cure Parkinson’s and Van Andel Institute. Professor Patrick Brundin is joined by sleep expert Dr Aleksander Videnovic, Professor Michele Hu consultant neurologist…
The Bristol GDNF results
Today – 27th February, 2019 – the long-awaited results of the Phase II GDNF clinical trial were published. GDNF (or glial cell line-derived neurotrophic factor) is a protein…
GDNF trial results published
Results from a pioneering clinical trials programme that delivered an experimental treatment directly into the brain of people with Parkinson’s offer hope that it may be possible to restore…
GDNF – The phase 2 Bristol trial
In February 2019, the results of the ground-breaking phase 2 Bristol study investigating the use of a neurotrophic factor called GDNF (Glial cell-derived neurotrophic factor) in people with Parkinson’s…
The UP Study – UDCA in Parkinson’s
Today we received word of a new clinical trial for Parkinson’s being initiated here in the UK. This trial – named the UP study – will evaluate the…
The Australian Parkinson’s Mission
At 9am on the 30th January, 2019, the Australian Government Federal Health Minister Greg Hunt announced the initiation of the ‘Australian Parkinson’s Mission‘ – a very massive $30…
The Australian Parkinson’s Mission (APM)
The Australian Parkinson’s Mission (APM) – is an international collaboration between the Garvan Institute, Shake It Up Australia Foundation, Parkinson’s Australia, Cure Parkinson’s and the Michael J. Fox Foundation….
Exciting Exenatide Exosomes
Recent analysis of blood samples collected during the Phase II clinical trial of Exenatide in Parkinson’s has uncovered a very interesting finding that could have major implications for…
Webinar – Targeting the Genetics of Parkinson’s
Presented by the Journal of Parkinson’s Disease, Cure Parkinson’s and Van Andel Institute. In this webinar Professor Patrick Brundin is joined by fellow panellists: Dr Ziv Gan-Or from the…
Webinar – Does Exenatide reduce Non-motor Symptoms in Parkinson’s?
Presented by the Journal of Parkinson’s Disease, Cure Parkinson’s and Van Andel Institute. Professor Brundin is joined by fellow panelists Professor Tom Foltynie (UCL) who led the recent exenatide…
Tom Isaacs award winners 2018 – Prof. Bas Bloem & Dr Simon Stott
Cure Parkinson’s and Van Andel Research Institute have announced Dr. Simon Stott (above left) and Professor Bastiaan Bloem (above right) as joint recipients of this year’s ‘Tom Isaacs Award’….
Webinar – How Does Parkinson’s Disease Begin? Neuroanatomical Pathways, Prions and Histology.
Professor Patrick Brundin is joined by fellow panellists Dr Filip Scheperjans a clinical neurologist working in Helsinki, Dr Jon Stamford a neuroscientist and person living with Parkinson’s, and Dr…
Alison Anderson – Fundraiser of the Year 2017
Fundraiser of the Year 2017 The Fundraiser of the Year Award recognises the individual who has ‘gone above and beyond’ to raise funds and/or awareness for Parkinson’s. We are…
The lixisenatide trial
Another trial in the promising diabetes drug cohort for repurposing in Parkinson’s is evaluating the effect of lixisenatide on the progression of Parkinson’s. This trial is co-funded by Cure Parkinson’s…
Tom Isaacs Award winner 2017 – Prof. Tom Foltynie
Cure Parkinson’s and Van Andel Institute (VAI) are proud to announce Professor Tom Foltynie, Consultant Neurologist and Researcher at University College, London, as the inaugural winner of the Tom Isaacs Award….
Our BBC Lifeline Appeal presented by Gavin Hastings
Former Scotland and British Lions captain Gavin Hastings presented the Cure Parkinson’s BBC Lifeline Appeal (a monthly charity appeal programme) which was broadcast on BBC One on Sunday 19th March 2017 and…
David Sangster – Fundraiser of the Year 2016
Fundraiser of the Year 2016 The Fundraiser of the Year Award recognises the individual who has ‘gone above and beyond’ to raise funds and/or awareness for Parkinson’s. We are…
Norman Yarrow – Fundraiser of the Year 2015
Fundraiser of the Year 2015 The Fundraiser of the Year Award recognises the individual who has ‘gone above and beyond’ to raise funds and/or awareness for Parkinson’s. You can’t…
Rosemary Mason – Fundraiser of the Year 2014
Fundraiser of the Year 2014 The Fundraiser of the Year Award recognises the individual who has ‘gone above and beyond’ to raise funds and/or awareness for Parkinson’s. The winner…
Alex Flynn – Fundraiser of the Year 2013
The Fundraiser of the Year Award recognises the individual who has ‘gone above and beyond’ to raise funds and/or awareness for Parkinson’s. Alex Flynn was the first recipient, becoming…